Navigation Links
PrimeraDx Names Fayyaz Memon Vice President of Regulatory Affairs and Quality Assurance
Date:8/2/2011

MANSFIELD, Mass., Aug. 2, 2011 /PRNewswire/ -- PrimeraDx today announced that Fayyaz Memon has been appointed to the position of Vice President of Regulatory Affairs and Quality Assurance.  

"We are very pleased to have Fayyaz join our team during such an exciting period for the Company," stated President and CEO Matthew McManus.   "Fayyaz comes at a key time, as we've recently launched our first product based on our unique technology for multiplex quantitative PCR, and we will be going to the FDA for clearance later this year.  Fayyaz will bring much needed expertise to take our Quality Systems to the next level and manage our regulatory submissions."

Mr. Memon joins PrimeraDx with over 20 years of experience as an executive in the life sciences and chemical industries.  He has held management positions with Thermo Fisher Scientific, Digene, Johnson&Johnson and SmithKline Beecham and has helped numerous companies to obtain FDA clearances and approvals and to establish quality systems.  He has a unique background covering quality systems, regulatory affairs, FDA remedial actions, software and process validation, manufacturing, and clinical trial services.  Mr. Memon earned his MBA in Operation and Quality Management and MS in Mechanical Engineering from Drexel University.  

"It is a very exciting time to join PrimeraDx!  Not only has the company recently begun commercialization of its core technology, but we are also poised to be a leader in the field of personalized medicine," commented Mr. Memon.  "I believe the product pipeline at PrimeraDx will have a significant impact on patient management, and will help realize the value of genomic medicine."

About PrimeraDx

PrimeraDx is dedicated to the high growth field of molecular diagnostics.  The Company has developed a unique platform for high-multiplex, quantitative, real-time PCR based on its proprietary STAR technology, implemented on the walk-away ICEPlex® instrument system.  PrimeraDx is developing a broad range of applications in oncology, infectious disease, companion diagnostics and multiple non-clinical molecular markets, both through its own efforts and in collaboration with partners.  The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation.  The Company's website is: www.primeradx.com or www.multiplexpcr.com.

CONTACT: Andrew Bond, 508-618-2300, info@primeradx.com


'/>"/>
SOURCE PrimeraDx
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US
2. Axial Biotech Names New VP of Reimbursement and Regulatory Affairs
3. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
4. Genstruct Names Louis Latino VP of Sales
5. Codexis Names Vice President, Intellectual Property
6. New England Peptide Names Director of Chemical Development
7. Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
8. Board of Directors of Milestone Scientific Names Joseph DAgostino Chief Financial Officer
9. PercSys Names David Auth and Howard Palefsky to Its Board of Directors
10. Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production
11. BioAuthorize Holdings, Inc. Names New Directors and Executive and Unveils Modification to Its Voice Biometric Authentication Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , ... January 17, 2017 , ... ... re-engineered Drug Safety Technology Consortium™ (SafeTEC™), $3 million in investment towards 15+ TEC ... new tools and assays, and their applicability in drug safety assessment, for the ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... and epigenetics research, recently announced a collaboration with the Heidelberg University Hospital and ... method for library preparation, following the company’s successful launch of its CATS ...
(Date:1/17/2017)... -- On January 10 at the Medtech Showcase held in ... in San Francisco , ProclaRx CEO, ... pharmaceutical leaders and public and private investors about the ... destroy biofilms.  Biofilms are a physical ... body,s immune system from eradicating chronic infections. Infections with biofilms ...
(Date:1/16/2017)... MANHASSET, N.Y. , Jan. 16, 2017   ... Kevin J. Tracey, MD , president and CEO of ... Northwell Health, completed an analysis of how the nervous ... further identify and develop bioelectronic medicine devices ... today in Nature Neuroscience . The ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016 "Increase in mobile transactions is driving ... biometrics market is expected to grow from USD 4.03 ... at a CAGR of 29.3% between 2016 and 2022. ... growing demand for smart devices, government initiatives, and increasing ... component is expected to grow at a high rate ...
(Date:12/7/2016)... BioCatch , the global leader in behavioral biometrics, reported a ... over 40 granted and pending patents. ... , The Company,s IP portfolio expansion ... Device, and Method Estimating Force Applied to a Touch Surface, " ... components needed to estimate the force and pressure applied to touch surfaces ...
(Date:12/6/2016)... Dec. 6, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... today a five (5) year funding commitment by ... expand the rehabilitation and reentry support to more ... Established in 2004, the Prison Entrepreneurship Program (PEP) ...
Breaking Biology News(10 mins):